As one of the hottest terms in 2024, "new quality productivity" is not only an upgrade of economic terms, but also a reflection of the process of era change, hiding the pulse of future industrial development. In many reports and documents issued by the state this year, the field of life sciences is closely linked to new quality productivity. At present, Beijing, Shanghai, Guangdong, Chongqing, Zhejiang, Jiangsu and other provinces and cities have successively issued documents to promote the development of new quality productivity and detailed implementation.

At present, the field of life sciences is in a period of rapid change, showing unprecedented vitality. After returning to China after studying abroad, many outstanding scholars have greatly promoted the development of this field, especially the development of basic medical research, biotechnology innovation, biopharmaceuticals, clinical diagnosis and treatment. The development is particularly prosperous.

Although the medical industry is treacherous, the rules are always the same: the vibrations and sounds from afar will give every keen person a hint. The trend of global capital grabbing land is particularly evident in the field of life sciences. Multinational companies have integrated their layout globally and expanded in the Chinese market, gradually forming a relatively large industrial structure.

Against this background, the power of capital has played a vital role and reshaped the evolution path of the field of life sciences. Many successful companies have made cross-border investments one after another, especially focusing on the frontiers of precision medicine and vaccine research and development. They either incubate big health-related departments internally or use investment and mergers and acquisitions to actively expand their territory in the health industry, which undoubtedly promotes the field of life sciences to a new height and accelerates the process of transforming life science results into practical applications.

It can be seen that the deep attention of capital has provided sufficient R&D funds and market support for the field of life sciences, and promoted the rate of technological innovation and industrial upgrading. By investing in potential enterprises and projects, it not only promotes the birth and application of new technologies, but also accelerates the upgrading of traditional industries and the competition and cultivation of talents.

With the support of various forces such as the scientific community and the capital community, China's scientific and technological innovation in the field of life sciences has gradually taken the lead in the world and gained a position. In particular, cell and gene therapy (CGT) technology has made major breakthroughs in the treatment of cancer, genetic diseases and other diseases. Many achievements have been achieved from scratch, from import to domestic production, so that the presence of Made in China has begun to spread all over the country, ushering in the best overspeed moment. It should be pointed out in particular that the wide application of flow cytometry in the fields of tumor immunotherapy and precision medicine is of milestone significance.

At the glorious moment of the 75th anniversary of the National Day, all walks of life in China are bathed in the joy of celebrating the prosperity of the country. The development of domestic forces is particularly eye-catching, showing an unprecedented strong momentum. In this era, as an excellent enterprise that has taken the lead in breaking through in the industry, Kuangbo Bio seems to have always adhered to a set of refined growth maps that resonate with the country. This has not only become the most curious point in the industry, but also a microcosm of the rise of domestic forces.

To this end, Ms. Zhao Qian, senior vice president of Weidu Bio and general manager of Kuangbo Bio, spoke to the media under the spotlight about the accumulation and achievements of the company's close follow-up to the country. At the same time, she also made a profound interpretation and prediction of future industry changes from a unique perspective, demonstrating Kuangbo Bio's confidence and foresight as the backbone of domestic forces.

As a company whose main business is the research and development and production of biological reagents for scientific research and clinical diagnosis, Kuangbo Bio's scientific research background can be traced back to the 1980s. At the time when the domestic life science industry was in its infancy, high-end reagents were often imported. At that time, Kuangbo Bio's entrepreneurial team hoped to bring the experience and ability of foreign product production back to China, establish a world-class scientific research reagent brand belonging to China, and support scientific research innovation and development. This initiative benefited from the foresight of the top scientists in the industry. They had a keen insight into industry trends, laid out early, and worked hard in this fertile land.
Faced with the initial market stereotype of domestic reagents, Kuangbo Bio chose to quietly accumulate strength and build a brand with quality. At the same time, with the help of national policies and funds, Kuangbo Biotechnology has gradually accumulated strong strength, and finally emerged in the new era, leading the new development of the local flow industry. It is worth noting that Kuangbo Biotechnology is one of the earliest Chinese companies to make flow reagents in China.

The technology platform established by the company is based on the mature industrialization, product development capabilities and technology platform experience of large international companies, and the starting point is quite high. Looking back at the development process of Kuangbo Biotechnology, it has undertaken 13 major national projects in the past ten years. It is the first company in China to obtain the Class III reagent registration certificate for lymphocyte subset detection reagents. The results of the transformation have filled the domestic gap and achieved import substitution.

Ms. Zhao Qian said that in flow diagnostic reagents, Kuangbo Biotechnology has formed a full industrial chain from antibody development to purification labeling, from scientific research reagents to clinical registration products, from reagents to equipment. At this moment, the flow product line combination is the most complete one among domestic and even international flow companies, covering a variety of lymphocyte subset detection kits, cytokines, flow antibodies, absolute counting and flow cytometers, etc. The product performance has been widely recognized by domestic users.

In an era of rapid change, there are many core elements to drive the company forward, and there are many ways to create high-quality and high-value products. What are Kuangbo Bio's strategies?
Ms. Zhao Qian pointed out that one of the cores of achieving good results is also the cultivation of talents. It is reported that cultivating talents to feed back the market is what Kuangbo has been doing continuously. In the more than ten years of building product growth, it has also cultivated generations of talents. In this era when flow companies are springing up like mushrooms after rain, Kuangbo talents are shining everywhere. Kuangbo Bio was founded in 2009. The founders are all scientists who focus on immunology and other fields who returned from well-known overseas universities. They used their knowledge and experience to build Kuangbo Bio's innovation platform; later, they absorbed the monoclonal antibody research and development team of the Institute of Hematology, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology), adding strong support to the research and development capabilities.

As we all know, the life science industry has always been a multidisciplinary industry. International giants have long monopolized the market, and the road to substitution has high barriers. In recent years, with the support of national policies, the level of domestic scientific research and transformation has been continuously improved, and the performance and quality of domestic mainstream products have gradually become comparable to imported brands, which has laid an effective foundation for domestic substitution. Specifically: in terms of space, local products and services have a natural advantage of fast response speed; in terms of classification, laboratory reagents, equipment and consumables have greater space for domestic substitution; in terms of opportunities, medical insurance negotiations and centralized procurement have gradually become normalized, and companies need to reduce costs and increase efficiency, so they need to constantly seek new solutions for upstream raw materials.

How to fight a good battle of preparation? Ms. Zhao Qian believes that the underlying technology platform and product performance must be consolidated first. The basis of domestic substitution is product quality. Enterprises need to have solid underlying technology and form their own industrial chain based on self-research, so that they can match the performance and stability of imported products and solve the bottleneck problem. In terms of business horizontal expansion capabilities, the ceiling of the life science segment track is low. Reviewing the development of international giants such as Thermo Fisher, it can be found that the long-term development of enterprises requires continuous expansion of business layout. "We should seize the policy and market window period to accelerate the expansion of market share. The next 3-5 years will be a critical period for domestic substitution. We need to pay attention to the progress of similar companies in developing domestic customers and enhancing stickiness. In terms of overseas market development, policy support provides life science companies with a rare opportunity to go overseas. Companies with excellent product quality need to strengthen overseas brand building. Coordinated development at home and abroad can open up the growth ceiling for companies. We should pay attention to domestic industry standards. China needs to participate more in the formulation and promotion of international and domestic standards for the life science industry. By participating in the standard-setting process, companies can enhance their voice in the global life science market." Ms. Zhao Qian emphasized. In general, local companies have certain strengths and opportunities to break the international monopoly, but they need to continuously improve in technology, quality, service and other aspects to meet market demand and gain wider recognition.

https://mp.weixin.qq.com/